Le Lézard
Classified in: Health
Subject: SVY

European Prenatal Genetic Testing Market Revitalised by Advancements in NGS and NIPT Technologies


Growth opportunities supported by implementation of cloud computing, collaborative business models and Big Data application, finds Frost & Sullivan

LONDON, Jan. 22, 2018 /PRNewswire/ -- Frost & Sullivan's latest analysis of the European prenatal genetic testing market point to advancements in technologies, such as next-generation sequencing techniques (NGS) and use of non-invasive prenatal testing (NIPT), as the key factors triggering market growth. The new research, Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021, projects that the market will reach $615.7 million by 2021 at a compound annual growth rate (CAGR) of 9.6 percent.

Frost & Sullivan expects the transitioning to NGS, implementation of cloud computing platforms, application of Big Data for in-house data interpretation and collaborative business models to open new growth opportunities. Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021 provides an analysis of key market dynamics, drivers, restraints, forecast and trends, market growth opportunities, segments to watch, and competitive analysis.

To access more information on this analysis, please click here.

"With only 60 to 70 per cent of pregnant women presently opting for prenatal testing, there is wide scope for increased penetration," said Frost & Sullivan Transformational Health Senior Industry Analyst Aarti Chitale. "Taking steps toward increasing physician and patient awareness and adoption of cutting-edge technologies such as NGS are expected to give the prenatal testing market much-needed revitalisation."

Whilst a major portion of the market is dominated by four to five United States-based participants, Aarti recommends a strong reliance on partnering with regional clinical labs and government-aided labs alongside research collaborations. Through these collaborations, market leaders will be able to penetrate the region, including Eastern European countries.

Further strategic imperatives for growth in the European prenatal genetic testing market include:

"Despite notable growth opportunities, strict regulations toward genetic testing across the European continent could hamper market growth," observes Aarti. "Moreover, the higher cost of NIPT tests, which are not consistent across different labs, could have a direct impact on the use of prenatal genetic tests."

Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021 is part of Frost & Sullivan's Transformational Health Growth Partnership Services Program.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Growth Opportunities in European Prenatal Genetic Testing Market,
Forecast to 2021
MD52-55

Contact:
Kristina Menzefricke
Corporate Communications ? Frost & Sullivan, Europe
P: +44 (0)208 996 8589
E: [email protected]
http://www.frost.com

http://ww2.frost.com
Twitter: @FS_Healthcare  
LinkedIn: Transform Health


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: